Ramai D, Shapiro A, Facciorusso A, et al. Immune checkpoint inhibitor therapy for hepatocellular carcinoma. Ann Gastroenterol. 2022;35(6):568–76.

PubMed  PubMed Central  Google Scholar 

Xie Y, Kong W, Zhao X, et al. Immune checkpoint inhibitors in cervical cancer: current status and research progress. Front Oncol. 2022;12: 984896.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheng W, Kang K, Zhao A, et al. Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer. J Hematol Oncol. 2024. https://doi.org/10.1186/s13045-024-01581-2.

Article  PubMed  PubMed Central  Google Scholar 

Qilu Pharmaceutical. Iparomlimab and tuvonralimab: Chinese prescribing information. 2024. https://www.hnysfww.com/data/m_c/1728497267153795099.pdf. Accessed 18 Oct 2024

Zhao Y, Ma Y, Zang A, et al. First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors. J Hematol Oncol. 2023. https://doi.org/10.1186/s13045-023-01445-1.

Article  PubMed  PubMed Central  Google Scholar 

Huang Y, Yang Y, Zhao Y, et al. QL1706 (anti-PD-1 IgG4/CTLA-4 antibody) plus chemotherapy with or without bevacizumab in advanced non-small cell lung cancer: a multi-cohort, phase II study. Signal Transduct Target Ther. 2024. https://doi.org/10.1038/s41392-023-01731-x.

Article  PubMed  PubMed Central  Google Scholar 

American Cancer Society. Treatment options by stage of nasopharyngeal cancer. 2024. https://www.cancer.org/. Accessed 22 Nov 2024.

Huang Y, Zhao S, Qu S, et al. Safety and efficacy of iparomlimab and tuvonralimab in combination with gemcitabine and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 trial (DUBHE-N-302) [abstract no. 6026 plus poster]. J Clin Oncol. 2024;42(16 Suppl).

American Cancer Society. Immunotherapy for colorectal cancer. 2024. https://www.cancer.org/. Accessed 22 Nov 2024.

Qilu Pharmaceutical. Qilu Pharmaceutical's blockbuster class 1 new drug has been approved for marketing, and it is expected to make new breakthroughs in the treatment of cervical cancer [media release]. 30 Sep 2024. https://www.qilu-pharma.com/.

Sound Biologics. Sound Biologics announces breakthrough approval of PSB205 by the National Medical Products Administration in China [media release]. 16 Oct 2024. https://www.soundbiologics.com/.

Fanslow WC, Liu Z, Hu ZH, et al. Development of PSB205, a bifunctional MabPair product that targets PD-1 and CTLA-4 [abstract no. 4069]. Cancer Res. 2019;79(13 Suppl).

Zhang L, Zhao HY, Ma YX, et al. Development and preliminary clinical activity of QL1706 (PSB205), a combination of anti-PD1 and anti-CTLA-4 antibodies manufactured together as a single product [abstract no. CT119 plus poster]. Cancer Res. 2021;81(13 Suppl).

Chugh R, Wang J, Olszanski A, et al. Safety of dual checkpoint-blockade with PSB205, an anti-PD-1/CTLA4 monoclonal antibody combination, manufactured and dispensed as a single product: a phase 1 study [abstract no. 2611 plus poster]. J Clin Oncol. 2022;40(16 Suppl).

Sound Biologics. MabPair™ Platform. 2024. https://www.soundbiologics.com/. Accessed 19 Nov 2024.

Liu Z, Hu Z, Shen M, et al. Development of MabPair technology, a novel platform for bifunctional antibody product [abstract and poster]. 2019. https://www.soundbiologics.com/. Accessed 20 Nov 2024.

Lou H, Zhou Y, Li D, et al. Efficacy and safety of iparomlimab and tuvonralimab in previously treated patients with recurrent or metastatic cervical cancer: a multicenter, open-label, single-arm, phase 2 clinical trial (DUBHE-C-206) [abstract no. 251 plus presentation]. Int J Gynecol Cancer. 2024;34(Suppl 1):A5.

Liu N, Yang Z, Tang D, et al. First-line iparomlimab and tuvonralimab (QL1706) + chemotherapy (chemo) ± bevacizumab (BEV) for recurrent or metastatic cervical cancer (r/mCC): updated results of the phase II DUBHE-C-204 study (abstract no 373O plus presentation). Ann Oncol. 2024;35(Suppl 4):S1544.

Article  Google Scholar 

Fang W, Yang Y, Zhao Y, et al. Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for epidermal growth factor receptor inhibitor (EGFRi)-resistant, EGFR-mutant, advanced non-small cell lung cancer (NSCLC): updated results from Cohort 5 in the DUBHE-L-201 study [abstract no. 646P plus poster]. Ann Oncol. 2024;35(Suppl 4):S1646.

Fan Y, Wang Z, Yang R, et al. Safety and efficacy of QL1706 plus carboplatin/etoposide (EC) as first-line (1L) treatment for extensive-stage small-cell lung cancer (ES-SCLC): the results from a phase II single-arm study [abstract no. 8525 plus poster]. J Clin Oncol. 2023;41(16 Suppl).

Qin S, Fan J, Yang F, et al. Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy in first-line (1L) treatment of advanced hepatocellular carcinoma (aHCC): a randomized, open-label, phase II/III study (DUBHE-H-308) [abstract no. LBA38 plus presentation]. Ann Oncol. 2024;35(Suppl 2):S1229‐S30.

Bi F, Zhang Y-q, Gu S, et al. An open-label, multicenter, adaptive, phase Ib/II study of QL1706 or QL1604 plus bevacizumab as first-line treatment in patients with advanced hepatocellular carcinoma [abstract no. 4077 plus poster]. J Clin Oncol. 2023;41(16 Suppl).

Zhang W, Zhang T, Chen X, et al. Iparomlimab and tuvonralimab (QL1706) with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: an open-label phase II study [abstract no. 1414P plus poster]. Ann Oncol. 2024;35(Suppl 2):S883.

Li J, Bai Y, Li Y, et al. Efficacy and safety of iparomlimab and tuvonralimab (QL1706) in untreated metastatic colorectal cancer (mCRC) [abstract no. 77P plus poster]. Ann Oncol. 2024;35(Suppl 4):S1434.

Zhu Y, Jiang T, Fang L, et al. A randomized, double blinded, multicenter phase 3 study of platinum-based chemotherapy with or without QL1706 as adjuvant therapy in completely resected stage II-IIIb NSCLC [abstract no. TPS8606 plus poster]. J Clin Oncol. 2023;41(16 Suppl).

Zhang L, Huang Y, Fang L, et al. A phase III, multicenter, double-blinded, randomized, active-controlled study on the efficacy and safety of QL1706 with chemotherapy (CT) as first-line therapy for PD-L1-negative advanced or metastatic non-small-cell lung cancer (NSCLC) [abstract no. TPS9139 plus poster]. J Clin Oncol. 2023;41(16 Suppl).

National Medical Products Administration. Iparomlimab and tuvonralimab injection: approval notice. 2024. https://www.nmpa.gov.cn/. Accessed 25 Nov 2024.

National Medical Products Administration. Iparomlimab and tuvonralimab injection: conditional approval announcement. 2024. https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/20240930101946184.html. Accessed 25 Nov 2024.